Evidence map›Paper›PMID 41607764›Full record

ArticleWorld journal of gastrointestinal oncology2026

Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases.

En-Hui Dai, Shu-Hao Que, Huan Xu, Guo-Qiang Zhong, Zhen Zhang, Xu Liang, Shu-Wei Zhai, Yue-Tong Li, Jing-Jing Wang, Wei Feng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

En-Hui DaiThe Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China.
Shu-Hao QueDepartment of Radiotherapy, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou 310006, Zhejiang Province, China.
Huan XuDepartment of Clinical Medicine, Hebei University of Engineering, Handan 056300, Hebei Province, China.
Guo-Qiang ZhongDepartment of Clinical Medicine, Hebei University of Engineering, Handan 056300, Hebei Province, China.
Zhen ZhangDepartment of Radiation Oncology (Maastro), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht 6229 HX, Netherlands.
Xu LiangDepartment of Radiotherapy, The Sixth Affiliated Hospital of Nantong University, Yancheng Third People's Hospital, Yancheng 224002, Jiangsu Province, China.
Shu-Wei ZhaiDepartment of Radiation Oncology, Changzhou Jintan First People's Hospital, Changzhou 213000, Jiangsu Province, China.
Yue-Tong LiDepartment of Oncology, The First Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
Jing-Jing WangDepartment of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China.
Wei FengZhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310022, Zhejiang Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe liver represents a common site of distant metastasis in patients with esophageal cancer (EC). Conventional chemotherapy (CMT) presents limited efficacy for EC, and EC patients with liver metastases typically experience a poor prognosis, highlighting an urgent need to explore novel treatment approaches. This study evaluated the overall efficacy and safety of CMT

aimTo evaluate the efficacy and safety of first-line chemoimmunotherapy for EC patients with liver metastases and to analyze prognostic factors.

methodsThis retrospective study included 126 EC patients with liver metastases at Zhejiang Cancer Hospital between 2014 and 2024. Patients receiving CMT were compared with those receiving CMT + ICI. Analyzed variables included clinicopathological features, treatment history, characteristics of metastasis, systemic and local treatments, overall survival (OS), and treatment-related adverse events (TRAEs). Prognostic factors were evaluated using univariate and multivariate Cox proportional-hazards regression models. Finally, efficacy outcomes and TRAE profiles were compared between the two groups.

resultsA significant difference in median OS was identified between the two groups (10.8 months in the CMT group

conclusionFor EC patients with liver metastases, the combination of CMT and ICIs demonstrates significantly superior efficacy compared with CMT alone, while maintaining manageable TRAEs.

Indexed as

ChemotherapyEsophageal cancerImmunotherapyLiver metastasisLocal liver-directed therapy

Identifiers

PMID41607764
PMCPMC12836114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.